In an effort to ®nd an alternative nontoxic means of inducing the apoptosis potential in both androgen-dependent and hormone refractory prostate cancer cells, attention was focused on curcumin (turmeric), traditionally used in medicine and cuisine in India and other south-east Asian countries. The results indicate that curcumin is a novel and potent inducer of apoptosis in both androgen-dependent and androgen-independent prostate cancer cells. This was accomplished by down-regulating apoptosis suppressor proteins and other crucial proteins such as the androgen receptor. It is concluded that curcumin may provide an alternative, nontoxic modality by which the clinician may prevent the progression of prostate cancer to its hormone refractory state or to treat advanced prostate cancer by forcing them to undergo apoptosis. Prostate Cancer and Prostatic Diseases (2000) 3, 84±93.
Introduction
Prostate cancer is the most common neoplasm and the second leading cause of male death in the USA. 1 The inability and the frustration in the clinical management of prostate cancer is derived from the fact that, despite the development of several androgen ablative therapies, an effective therapeutic regimen is still lacking, especially for the treatment of hormone refractory prostate cancer. 2, 3 Therefore, development of mechanism-based treatment strategies is desperately needed. As a way to approach this problem, several investigators have recently turned towards strategies in alternative medicine, tapping into the vast traditional knowledge base available in various ethnic societies. Over the past few years, a number of foods, vitamins and minerals have been found to be bene®cial for the prevention and treatment of prostate cancer and other cancers. Selenium, vitamins A, C and E, garlic, green tea, soy bean, PC-SPES, to name a few, have been the topic of discussion in many recent publications. 4 ± 9 Efforts are being made in several laboratories, including ours, to augment, improve and supplement the current cure rates of prostate cancer by conventional therapies such as androgen ablation, radiation and chemotherapy with nature-based therapies. Evidence is mounting that we can prevent many illnesses such as prostate cancer by modifying our lifestyle, such as diet. 10 In an effort to search for alternative therapies for hormone refractory prostate cancer, attempts are being made in this laboratory to determine the ef®cacy of some holistic remedies and study the molecular mechanisms by which some dietary ingredients such as curcumin, traditionally used in India and other south-east Asian countries for thousands of years, in¯uence the genesis and progression of human prostate cancer to its advanced stages. Curcumin, popularly called turmeric (diferuloyl methane), the powdered rhizome of Curcuma longa L, has been used traditionally as a coloring and¯avoring additive in Indian and south-east Asian cuisine. It was also used to treat a variety of in¯ammatory conditions and chronic diseases. 11 ± 16 It displays anti-carcinogenic properties in animals, as indicated by its ability to inhibit both tumor initiation induced by benzo(a)pyrene-mediated DNA adduct formation and development of skin tumors, as well as tumor promotion induced by phorbol esters, possibly by inhibiting protein kinase C. 17 Importantly, dietary administration of curcumin during the initiation and post-initiation periods signi®cantly suppressed the development of chemically induced forestomach, duodenal and colon tumors in CF-1 mice. 18 It also reduced the formation of focal areas of dysplasia and aberrant cyptic foci in the colon that are the early preneoplastic lesion in the rodents. 19 In another important study, Kawamori et al showed that chemopreventive activity of curcumin could be observed even in the promotion/progression phase of colon carcinogenesis in experimental animals. 20 Consistent with the chemopreventive activity during all states of tumor formation, curcumin has also been shown to decrease the expression of proto-oncogenes such as c-fos, c-jun and c-myc, possibly through the inhibition of speci®c protein kinases. 21 Curcumin also has anti-tyrosine kinase activity against EGFreceptor in A431 cells and p185 neu in AU-565 cells. 22, 23 Moreover, several recent studies reported the occurrence of apoptosis or apoptosis like changes upon exposure to curcumin in human lymphoblastoid T (jurkat) cells and in human promyelocytic leukemia (HL-60) cells. 24, 25 Because curcumin has already been shown to have negligible systemic toxicity in animal and human studies and since it has been classi®ed under the`generally recognized as safe' or`GRAS' category by the chemoprevention branch of the National Cancer Institute (NCI), and since no study has been reported on the ef®cacy of curcumin in interfering with prostate carcinogenesis, we explored the effect of curcumin on cell proliferation and its apoptosisinducing potential in human prostate cancer cells. 26 ± 28 Materials and methods
Cell culture
The androgen-sensitive human prostatic carcinoma cell line LNCaP and its bcl-2 over-expressing relative (LNCaP-bcl-2) were maintained as described previously. 29 The androgen-independent prostate cancer cell line PC-3 was purchased from the American Type Culture Collection (ATCC, Manassas, VA) and maintained as recommended. All cells were maintained at 37 C in a humidi®ed atmosphere of 95% air and 5% CO 2 .
Treatment with curcumin and cell viability assays
The various prostate cancer cell lines were seeded in 96-well plates at a density of 5Â10 3 cells in 100 ml per well. Curcumin was purchased from Sigma and stored as a 50 mM stock solution in DMSO, protected from light at À20 C. Twenty-four hours after seeding, the medium was removed and replaced with fresh medium containing DMSO (vehicle only) or medium containing increasing concentrations of curcumin (usually 5 ± 50 mM) in a total volume of 100 ml, and the culture was maintained in the CO 2 incubator for a further period of 3 days. For each curcumin concentration and each time point, cultures were maintained in quadruplicates. At the end of the 24, 48 and 72 h periods, 10 ml of the MTT labeling solution was added from a cell proliferation assay kit obtained from a commercial source (Roche Diagnostics, Indianapolis, IN) and processed exactly as described by the manufacturer. After the solubilization of the purple formazan crystals was complete, the absorbance of each well was measured spectrophotometrically using a microtiter plate reader, using a ®lter for 570 nm.
Western blot analysis
(a) Apoptosis modulating proteins LNCaP parental cell and LNCaP-bcl-2 cells were treated with increasing concentrations of curcumin. The relative levels of apoptosis suppressor proteins such as bcl-2, bcl-X L and apoptosis promoter proteins such as bax were measured against a backdrop of actin protein, which was used as a negative control, using methods described previously. 29 The cells were lysed by treatment in RIPA buffer (10 mM Tris ± HCl, pH 7.4, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 150 mM NaCl containing 50 mg/ml of antipain, 40 mg/ml of pepstatin, 30 mg/ml of chymostatin, 1 mg/ml of leupeptin, 1 mg/ml of pepstatin, mg/ml of aprotinin and 1 mM phenyl methyl sufonyl¯uoride. Protein concentration was measured using a modi®ed Bradford assay (Bio Rad Laboratories, Hercules, CA). A blocking solution of 5% BSA was used instead of non-fat milk. The antibodies used were a mouse monoclonal anti-bcl-2 from Dako (Dako Corp, Carpinteria, CA), at 1 : 3000 dilution; a mouse monoclonal anti bcl-X L , from Santa Cruz (Santa Cruz, CA), at 1 : 3000 dilution; and a mouse monoclonal antibody for bax (Santa Cruz, CA, at 1 : 3000 dilution). After washing in Tris buffered saline containing 0.05% Tween 20, the ®lters were incubated with a 1 : 5000 diluted and corresponding secondary antibody conjugated with horseradish peroxidase (Santa Cruz, CA). After washing, the ®lters were treated with the enhanced chemiluminescence (ECL) solution mixture exactly as described by the manufacturer (Amersham, Arlington Heights, IL). The ®lters were exposed to X-OMAT AR X-Ray ®lm for times ranging from 30 s to 5 min.
(b) Markers relevant to prostate cancer Normalized amounts (25 or 50 mg) of proteins from the RIPA extracts prepared as described earlier were processed for Western blots in either 7.5% or 12% gels depending upon the size of the protein in question. The blots were blocked, probed and processed for ECL as described earlier with a monoclonal antibody for the human androgen receptor (Sata Cruz, sc-7305, at 1 : 3000 dilution) or with a mouse monoclonal antibody for the human prostate speci®c antigen (Santa Cruz, sc-7316 at 1 : 3000 dilution).
Analysis of apoptosis induced by curcumin
(a) Detection of apoptotic nuclei by the TUNEL method For this analysis, parental LNCaP cells were grown on cover slips as described above. Enzymatic in situ labeling of apoptosis-induced DNA strand breaks were done by the TUNEL (TdT mediated dUTP nick end labeling) method, Curcumin down-regulates apoptosis suppressor proteins T Dorai et al 85 using a commercially available kit (Roche Diagnostics, Indianapolis, IN), following a protocol described by the manufacturer.
(b) Detection of apoptotic cells by Annexin-V staining As an early indicator of apoptosis in LNCaP prostate cancer cells in response to exposure to curcumin, the rapid translocation and accumulation of the membrane phospholipid phosphatidyl serine (PS) from the cytoplasmic surface to the extracellular surface was followed. This loss of membrane assymetry was detected by using a FITCconjugated PS-binding protein Annexin-V (Santa Cruz). LNCaP cells, grown in cover slips as described earlier, were treated with the drugs for 12 h (instead of 24 h as described for DAPI or TUNEL staining procedures), and were washed free of the medium and incubated with the assay buffer containing Tris buffered saline with 2.5 mM CaCl 2 for 10 min at room temperature. The cover slips were then treated with Annexin-V-FITC diluted in the same assay buffer exactly according to the manufacturer's protocol. The cover slips were then mounted on glass slides and visualized using an Olympus¯uorescence microscope with a ®lter set for FITC.
(c) Analysis of apoptosis by PARP cleavage Parental LNCaP cells were exposed to increasing concentrations of curcumin as described earlier for 24 h. The¯oating and adherent cells were pooled, washed three times with 1ÂPBS to remove the medium and lysed in 1ÂRIPA buffer (10 mM Tris HCl,pH 7.4, 1% NP-40 0.5% sodium deoxy cholate, 0.1% SDS, 0.15 M NaCl containing a protease inhibitor cocktail as described earlier, (Roche Diagnostics, Indianapolis, IN). Normalized amounts of cell lysate protein (25 mg) were electrophoresced through 7.5% denaturing polyacrylamide gels. The resolved proteins were transferred to nitrocellulose and probed with a mouse monoclonal antibody against the human Poly ADP-Ribose Polymerase (PARP, Santa Cruz Biotechnology, Santa Cruz, CA) as described earlier in the Western blotting protocol and the ECL procedure was performed to visualize the protein bands.
Results
Curcumin diminishes the proliferative potential of human prostate cancer cells
As practically no published information was available on the effect of curcumin on the prostate system, our initial experiments focused on the effect of curcumin on the cell growth and proliferative potential of prostate cancer cells. LNCaP was chosen as the androgen-dependent prostate cancer cell line and PC-3 was chosen as the androgenindependent cell line, and they were grown in 96-well plates. Curcumin, dissolved in DMSO, was used at a concentration range between 0 and 50 mm. The cancer cell lines were exposed to the drug one day after seeding and their viability was followed for 3 days using the MTT cell proliferation assay. Results are presented as percentage of control growth on the corresponding day and each value was measured in quadruplicate. The cell proliferative potential of LNCaP and PC-3 are shown in Figure 1A and B, respectively. The ®gures shown that exposure to curcumin at a range between 20 and 50 mM strongly inhibited the growth of both cell lines by 60 ± 80%, indicating that this drug affects the cell proliferative rate of both androgen-dependent and androgen-independent prostate cancer cells in a dose-and time-dependent manner. The kinetics of the MTT assay curves suggest that the effect of curcumin could be both cytostatic and cytocidal. There was no growth inhibition of any of these prostate cancer cell lines by the DMSO vehicle (used at the same ®nal concentration of 0.1%). Later, another androgen-independent prostate cancer cell line DU-145 was also shown to be inhibited by exposure to curcumin in a similar manner (data not shown). There was a marked change in the morphology within 48 h of curcumin treatment, characterized by more round and¯oating cells, gradually increasing from concentrations from 20 to 50 mM. Results of other experiments showed that there was no effect of curcumin on the general protein synthesis of parental LNCaP cells by exposure to 20 mM curcumin for 6 h and the growth inhibition of LNCaP cells by curcumin (30 mM for 24 h) was not reversible (data not shown). It is worth noting that the IC 50 of curcumin on both LNCaP and PC-3 cells ranges from 10 to 20 mM, which is close to that of some of the conventional chemotherapeutic agents such as 5-¯uorouracil. 30 Moreover, since animal and human studies have shown that curcumin is generally safe with no untoward systemic toxicity, the potential therapeutic role of curcumin in androgendependent and hormone refractory prostate cancers merits further study, in addition to its well-established role as a chemopreventive agent.
Over-expression of bcl-2 does not protect LNCaP cells from the effects of curcumin:
The LNCaP derivative over-expressing the apoptosis suppressor protein bcl-2 has already been described in the earlier work from this laboratory. 29 Our previous work has shown that, while not affecting the proliferative properties or the expression of differentiated prostate speci®c gene products such as PSA and the androgen receptor, bcl-2 expression in LNCaP cells conferred resistance to apoptosis when these cells were grown in an androgen/steroid depleted medium in vitro and in vivo (ie after castration). 29 The derivatized cells were also resistant to several other apoptosis stimuli such as serum starvation and phorbol ester treatment. These earlier data suggested that the bcl-2 oncoprotein can protect prostate cancer cells from apoptosis in vitro and such protection correlates with the tumor-forming ability in the absence of androgens in vivo and could from a central working model for the genesis and maintenance of hormone refractory prostate cancer. 31 So, attempts were made to explore the role of bcl-2 protein in curcumininduced decrease in cell proliferation. Interestingly, the results shown in Figure 1C indicated that curcumin can decrease the proliferative potential of bcl-2 over-expressing LNCaP cells too in a time-and concentration-dependent manner, in the same way as the parental LNCaP and PC-3 cells. As a negative control, LNCaP cells expressing only the expression vector (neo 1 ) were used and were Figure 1 Treatment of parental androgen-dependent LNCaP cells (A), androgen-independent PC-3 cell (B) and LNCaP cells over expressing bcl-2 protooncogene (C) with curcumin promotes loss of cell viability. Twenty-four hours after seeding (day 0), cultures were supplemented with different doses of curcumin, as indicated. Cell growth was measured by the MTT cell proliferation assay. Each time point was measured in quadruplicates using 96-well culture plates and expressed as relative cell viability with respect to the untreated control for that corresponding day.
Curcumin down-regulates apoptosis suppressor proteins T Dorai et al 87 found to behave exactly the same way as the parental LNCaP (data not shown). Later, curcumin was also found to inhibit the proliferative potential of LNCaP cells overexpressing another apoptosis suppressor protein, bcl-X L (data not shown). These results strongly suggest that the expression of apoptosis suppressor proteins fail to protect prostate cancer cells from cell death induced by curcumin. This would imply that curcumin may be able to suppress cell proliferation and induce cell death through bcl-2 or bcl-X L -independent mechanisms.
Curcumin down-regulates the levels of apoptosis suppressor proteins and modulates the bax/bcl-2 ratio Next, we analyzed the changes in the expression of apoptosis modulating proteins such as bcl-2, bcl-X L and bax in parental LNCaP cells and compared them with the level of expression of a housekeeping gene such as actin at the protein level, in response to the exposure to curcumin at different concentrations (0 ± 50 mM). As shown in Figure 2A , the bcl-2 and bcl-X L levels are strikingly down-regulated by incubation with curcumin above a concentration of 20 mM in a period of 24 h. Parental LNCaP cells are known to express trace amounts of bcl-2 protein, which could be observed only after long exposure of the ECL blots to the X-ray ®lms. 29 In contrast, proteins such as bcl-X L and bax are expressed at a higher level than bcl-2 in LNCaP cells. 32 The expression of bcl-2 protein is undetectable at 30 mM concentration of curcumin or higher after a 24 h exposure. Similar decrease was observed with respect to the level of expression of another apoptosis suppressor protein bcl-X L . Interestingly, one other protein crucial to the regulation of the apoptotic process, namely bax, was essentially unchanged after exposure to curcumin. As a negative control, identical amounts of protein extracts were electrophoresced and the blots were probed for actin. This analysis showed negligible change after exposure to increasing concentrations of curcumin. Next, we examined whether the decrease in apoptosis suppressor protein bcl-2 would be true for bcl-2 over-expressing cell also. The results of the immunoblots of bcl-2 over-expressing LNCaP cells are shown in Figure 2B . A dramatic down-regulation of bcl-2 levels was seen in bcl-2 over-expressing cell too, as seen in the ®gure. In contrast, LNCaP cells transfected with the neo-resistant expression vector only (LNCaP-neo 1 ) behaved exactly like parental LNCaP cells (data not shown). These results highlight the intriguing property of curcumin in selectively down-regulating the apoptosis suppressor proteins while the levels of apoptosis promoting proteins are relatively unaffected. This would theoretically lead to a scenario where the bax/bcl-2 or bcl-X L ratio would be increased, pushing the cells towards initiating and progressing through the apoptotic process.
Curcumin induces apoptosis in both androgendependent and androgen-independent prostate cancer cells in a concentration-dependent manner
To determine whether curcumin-induced cell death demonstrates the characteristic features of apoptosis, we examined parental untreated LNCaP cells, LNCaP cells treated with 30 mM curcumin for 24 h or LNCaP cells treated for 24 h with 10 nM phorbol myristate acetate (PMA) as a positive control using several methods commonly used for the analysis of the apoptotic process. 29 The apoptotic DNA ladder pattern of curcumin-treated prostate cancer cells on agarose gels was not attempted, as this method provides neither information regarding apoptosis in individual cells nor information regarding histological localization. Hence, the enzymatic in situ labeling of apoptosis-induced DNA strand breaks using terminal deoxynucleotidyl transferase (TUNEL) procedure was performed on all three cell systems described above. The ®nal signal was converted with an antiuorescein antibody conjugated with horseradish peroxidase and visualized under a light microscope. As can be seen in Figure 3A , intense staining of the curcumintreated nuclei could be observed, which was qualitatively comparable with the TUNEL stain that could be obtained after treating parental LNCaP cells with phorbol myristate acetate as a positive control. In order to further characterize the morphological features to curcumininduced cell death, one of its earliest features, namely the changes in the plasma membrane, especially the translocation of the membrane phospholipid phosphatidyl serine (PS) from the inner lea¯et to the outer lea¯et of the plasma membrane was followed by the binding of thē uorescein isothiocyanate (FITC)-conjugated PS binding protein Annexin-V in the presence of Ca 2 ions. Loss of membrane integrity and externalization of PS could be observed in parental LNCaP treated with either curcumin or the PMA positive control, as early as 12 h after drug treatment, as seen by the intense FITC¯uorescence in Figure 3B as compared with the untreated control. Finally, in order to verify whether poly ADP ribose polymerase (PARP) proteolysis could be observed as an indicator of activation of the PARP protease (CPP32/prICE) as an early response to treatment of parental LNCaP cells with curcumin, Western blot analysis was performed on LNCaP cell lysates, treated with increasing concentrations of curcumin. The results are shown in Figure 3C . Proteolysis of PARP from the native 116 kDa protein to a characteristics 85 kDa fragment was visible from a curcumin concentration of 20 mM and above. All these data strongly suggest that curcumin treatment of the classical prostate cancer cell line LNCaP in accompanied by the phenomenon of programmed cell death.
Curcumin-induced apoptosis of LNCaP cells is accompanied by a down-regulation of the androgen receptor (AR) protein more dramatically than prostate-speci®c antigen (PSA)
Next, we wished to determine whether curcumin treatment of parental LNCaP cells, while initiating the process of apoptosis, had an in¯uence on the level of expression of typical prostate marker proteins such as the androgen receptor protein and prostate-speci®c antigen. The results of the Western blot analysis are shown in Figure 4 . As can be seen from Figure 4A , the androgen receptor protein is strikingly down-regulated in response to curcumin treatment. The reduction in the protein levels could be seen at curcumin concentrations as low as 10 mM and the AR, protein is virtually nonexistent at 30 mM. Interestingly, a Western blot analysis performed on the same cell lysates revealed a less dramatic reduction in the level of expression of the prostate-speci®c antigen protein, shown in Figure 4B . There was no change in the level of expression of the actin protein, which was found to be essentially the same as shown in Figure 2A (data not shown).
Discussion
This study was undertaken as part of an exploratory screening of holistic phytochemicals that are well known in speci®c ethnic societies and have both preventive and therapeutic potential in cancer, and to translate their potential into a clinical prostate cancer setting. One such candidate under consideration, namely curcumin, has received a lot of encouragement in recent studies, which reported that it could not only interfere with the initiation/promotion period of colon carcinogenesis but also with the promotion/progression period, meaning that it could be potentially useful in the treatment of pre-existing neoplasms. 17 ± 20 Although curcumin has several metabolic, cellular and molecular activities, recent studies have suggested that it can also act through mechanisms such as inhibition of cell proliferation and induction of apoptosis in colon tumors. 33 Hence, a hypothesis was proposed in this study that curcumin, on the basis of its established properties, may inhibit the proliferative potential and induce the apoptotic potential of prostate cancer cells and affect the signal transduction pathways so as to interfere with the progression of prostate cancer to its hormone refractory state.
Androgens regulate the growth and development of the prostate gland and are necessary for the maintenance of its functions. As the mainstay of the therapeutic modality for prostate cancer, androgen ablation methods induce an initial and impressive wave of apoptosis, by which most of the androgen-withdrawal sensitive prostate cancer cells are eliminated. However, a certain population of prostate cancer cells, called the androgenwithdrawal insensitive prostate cancer cells, which either by virtue of their pre-existence or by adaptation in an androgen depleted mileau, learn how to survive. 34 This is largely due to an enhanced expression of apoptosis suppressor proteins such as bcl-2 and bcl-X L in prostate cancer cells, which subsequently gain growth advantage to proliferate and metastasize to distal organs with a fatal outcome. 35, 36 Such a possibility was suggested by earlier work from our laboratory and others that bcl-2 overexpression in LNCaP cells confers an androgen-independent phenotype in LNCaP cells which enables them to grow in an androgen depleted medium in vitro and grow in vivo in castrated nude mice. 29, 37 Also, it is worth noting that an enforced expression of bcl-2 causes a more invasive phenotype in LNCaP cells. 38, 39 Hence, there is a desperate need to discover a non-androgen ablative means to kill the androgen-insensitive cancer cells of the prostate which do over-express these apoptosis suppressor proteins. In this regard, several important publications have revealed the fact that, despite offering resistance to several apoptotic stimuli such as androgen withdrawal, serum starvation or phorbol ester treatment, androgen-insensitive prostate cancer cells do in fact maintain the basic and apparently functional apoptotic machinery which could be activated under certain circumstances. 40, 41 So, a central aim of this study has been to test the hypothesis that the apoptotic machinery of the prostate cancer cells may be activated despite the presence of apoptosis suppressor proteins such as bcl-2 and bcl-X L for tumoricidal purposes and that the unwanted hormone refractory prostate cancer cells can be forced to commit to apoptosis. Hence, a down-regulation of proteins such a bcl-2 and bcl-X L will have signi®cant therapeutic bene®ts in a major fraction of prostate cancer patients who over-express these proteins. In this respect, curcumin offers itself as the most promising candidate in that it induces apoptotic potential not only in androgensensitive prostate cancer cells such as LNCaP, but also in PC-3 cells and in the androgen-insensitive LNCaP cells with an enforced expression of the apoptosis suppressor proteins bcl-2 or bcl-X L .
Earlier work from this laboratory also suggested that ablation of bcl-2 expression with the help of a speci®c anti-bcl-2 ribozyme promoted apoptosis in bcl-2 expressing human prostate cancer cells. 42 ± 44 But the results reported in this study reveal the facts that ®rst, curcumin Curcumin down-regulates apoptosis suppressor proteins T Dorai et al may even be superior to agents like the mRNA-speci®c ribozyme in that it down-regulates not only bcl-2 but also bcl-X L ; second, no gene therapeutic adenoviral or retroviral protocols need to be drawn; third, it can be used both in the chemopreventive and the therapeutic modes by introduction in the diet; and fourth and most importantly, curcumin exerts its bene®cial effects at a negligible fraction of the cost compared with the gene therapy protocols or even the natural estrogen-based protocols such as PC-SPES. 45 The most important statement that one can make from this study is that curcumin is probably the most effective and the least expensive of all reagents by which one can bypass the apoptosis resistance of hormone refractory prostate cancer cells. It would be very interesting to see whether curcumin can still activate proteases such as caspases 3 and 7 and facilitate the accumulation of cytochrome c in the cytosol despite an over-expression of bcl-2 in prostate cancer cells. 46 Because caspase activation occurs downstream of the bcl-2 checkpoint, the effect of curcumin may have signi®cant clinical implications. 47 It is highly possible that curcumin activates speci®c caspases that induce apoptosis in prostate cancer cells that over-express bcl-2 and bcl-X L . Studies are under way in the laboratory to decipher these processes. Also, it should be mentioned here that, while the effect of curcumin meets most of the stringent criteria set for the phenomenon of apoptosis such as the modulation of bcl-2 and bcl-X L levels, DAPI and TUNEL staining and Annexin-V staining, the cleavage of the PARP protein precursor to the 85 kDa proteolytic fragment is not quantitative, unlike other apoptosis inducers such as etoposide, which raises the possibility that curcumin may bring up other forms of cell death in addition to the apoptotic cell death process. 25 Bax and bcl-2 are two discrete members of the gene family involved in the regulation of cellular apoptosis. Even though these two genes share partial amino acid sequence homology in their functional domains, their individual protein products appear to have opposing functions with regards to their effects on the apoptotic sensitivity of a cell. Pro-apoptotic bax and anti-apoptotic bcl-2 family members can heterodimerize and seemingly titrate out each other's function, suggesting that their relative concentration may act as a rheostat for the cell suicide program in the sense that their intracellular ratio can profoundly in¯u-ence the ability of a cell to respond to an apoptotic signal. Even though the current experimental evidence indicates that there are a few subtle exceptions , as a general rule of thumb, the rheostat theory still holds good in that a cell with a higher bax/bcl-2 ratio will be more sensitive to a given apoptotic stimulus when compared to a similar cell type with a relatively low bax/bcl-2 ratio. 48, 49 The modulation of protein levels in bax and bcl-2 shown in this study is consistent with and supports this view.
The observation that curcumin is able to down-regulate bcl-X L proto-oncogene too, apart from bcl-2 in the prostate cancer cells, would have more theoretical and therapeutic implications. Bcl-X L protein expression has also been found in the epithelial cells of the normal prostate gland, where it has been speculated to contribute to the hormonal control of programmed cell death. 36 In the same publication, it was reported that out of 64 cases of the adenocarcinoma of the prostate, all (100%) stained positively for the bcl-X L protein.
More over, the intensity of staining and the percentage of immunopositive cells seemed to be directly correlated with the Gleason score. 36 Whereas bcl-2 over-expression is found in a small subset of the adenocarcinomas of the prostate, it is found far less commonly than bcl-X L . 35 When overexpressed in cell systems such as the prolymphocytic leukemia cell line FL5.12, bcl-X L , was found to profoundly interfere with the apoptotic stimuli of various chemotherapeutic agents. 50 It has been proposed that the presence of the anti-apoptotic protein bcl-X L expressed in prostate cancer cells may be related to the relative resistance to chemotherapy in clinical prostate cancer. This observation, when added to the differences in the subcellular localization between these two proteins, would strongly suggest that these two proteins are under two different regulations and that bcl-2 and bcl-X L would modulate different paths in the prevention of apoptosis in the prostate cancer cells that are mutually exclusive or independent. 51, 52 It is signi®cant that, in spite of these differences, curcumin is able to bypass the two different styles of apoptosis resistance mediated by these two key players, by interfering with a common denominator in their function which is yet to be characterized.
Androgen receptor is a critical factor for cell growth both in the normal prostate and in prostatic carcinoma. Prostate tumors, especially the ones as exempli®ed by LNCaP, adapt to an environment of low or no androgen supply by using a hyperactive androgen receptor. In approximately 30% of cases in which the tumors re-emerge after androgen ablation, cancer cells show high levels of AR gene ampli®cation with a concomitant elevation in the level of functional AR. 53 Irrespective of the AR gene ampli®cation, increased AR expression appears to be the single and selective driving force for the progression of prostate cancer to the hormone refractory phase. 54 A similar phenomenon was observed in the LNCaP prostate cancer derived subline 104-R. 55 In this report, transition from the clonal subline LNCaP 104-S during prolonged passage in an androgen-depleted medium to the subline 104-R was accompanied by an accelerated growth phase and a 15-fold increase in the androgen receptor protein level compared with the parental LNCaP controls. Thus, prostate cancer that recurs after androgen deprivation therapy is clearly androgen receptor dependent if not androgen dependent. However, the exact mechanism that produces a high level of activated androgen receptor is still unknown and may be due to the presence of growth factors or protein kinase A mediated pathways that elicit a ligand-independent activation of the androgen receptor. 56, 57 Irrespective of the activation mechanism, a speci®c down-regulation of the androgen receptor protein in LNCaP cells after curcumin treatment, as observed in this study, is expected to deprive these cells of a critical growth advantage and quali®es this phytochemical for a nontoxic therapeutic approach to the management of AR-dependent prostate cancer.
In conclusion, curcumin, whose medicinal properties are mentioned in ancient vedic scriptures of India, may be the most novel and appropriate naturally occurring reagent ever (re)discovered for reducing the tumor burden of the prostate cancer patient. Studies are under way in the laboratory to evaluate the ef®cacy of this compound in nude mice bearing LNCaP prostate cancer as explants. Results presented in this study strongly suggest that the bene®cial effects curcumin begin where those of the conventional anti-androgen therapies end as it would kill both androgen-dependent and androgen-independent tumor cells by forcing them to undergo apoptosis or apoptosis-like changes irrespective of whether these cells express one or multiple apoptosis suppressor proteins. Animal and human studies have indicated that systemic toxicity of curcumin is negligible. 26, 27 Hence, in addition to its activity as a chemopreventive reagent, the potential therapeutic role of curcumin in advanced prostate cancers is worthy of further investigations and clinical trials. Or, at least, either dietary or systemically administered curcumin would synergize with the known anticancer agents for prostate cancer therapy such as taxol and estramustine to bring up a better kill at a lower anticancer drug concentrations, thus improving the quality of life of the prostate cancer patient. 58 
